In vivo CAR-T delivery demands highly consistent, scalable, and high-purity lentiviral vector (LV) production. Conventionaltransient transfection frequently introduces batch variability in titer, envelope composition, and impurity profiles, posingchallenges for reproducible pharmacodynamics and clinical safety.
Stable producer cell lines ensure uniformity of viral vector composition, supporting predictable quality and robustmanufacturing scale-up without repeated process re-optimzation. This approach enables higher volumetric productivityreduced variability, and a more reliable supply of clinical-grade LV for in vivo CAR-T applications.
High-quality vectors: These cell lines produce high-titer lentiviral vectors with good transductionefficiency, specificity, and batch-to-batch consistency.
Scalable and manufacturable: High titers, combined with robust suspension growth and viability,support process scalability and manufacturability.
Advantageous for in vivo CAR-T therapies: Data indicate that stable producer cell lines are a superiormethod for in vivo lentiviral vector production compared to conventional approaches.
+86-0755-86562586
.jpg)
